Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Hyperfine, Inc. - SIC # 3840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
HYPR
Nasdaq
3840
www.hyperfinemri.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Hyperfine, Inc.
Hyperfine to Present at the Piper Sandler 38th Annual Healthcare Conference on December 3
- Nov 19th, 2026 2:30 pm
Hyperfine (HYPR) Q3 2026 Earnings Call Transcript
- Nov 10th, 2026 9:29 am
Hyperfine, Inc. Q3 2026 Earnings Call Summary
- Nov 10th, 2026 6:30 am
Hyperfine Inc (HYPR) Q3 2026 Earnings Call Highlights: Record Revenue, 73% Growth, and First ...
- Nov 10th, 2026 12:09 am
What Hyperfine (HYPR) Said on Its Q3 Earnings Call
- Nov 9th, 2026 7:14 pm
Hyperfine, Inc. Reports Third Quarter 2026 Financial Results
- Nov 9th, 2026 2:05 pm
Hyperfine to Participate in Jefferies London and BTIG Tech-Enabled Healthcare Conferences
- Nov 3rd, 2026 2:05 pm
Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness
- Oct 22nd, 2026 6:15 am
Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% Sequentially
- Oct 8th, 2026 6:33 am
Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026
- Oct 8th, 2026 5:30 am
Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million
- Oct 8th, 2026 5:30 am
Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets
- Sep 28th, 2026 6:15 am
MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award
- Sep 16th, 2026 6:00 am
Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
- Sep 15th, 2026 6:15 am
Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
- Aug 31st, 2026 6:15 am
Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
- Aug 26th, 2026 6:15 am
Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings
- Aug 20th, 2026 6:15 am
Hyperfine (HYPR) Q2 2026 Earnings Call Transcript
- Aug 13th, 2026 6:16 pm
Hyperfine, Inc. Q2 2026 Earnings Call Summary
- Aug 7th, 2026 6:30 am
Scroll